Targeting BTK to treat CLL and NHL: insights from BTKis and novel BTK degraders
In this video, Tanya Siddiqi, MD, City of Hope, Duarte, CA, Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, and Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, share insights into the targeting of BTK as a treatment for chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). They focus on insights that have been learned from the approved BTK inhibitors (BTKis) and the promising development of novel BTK degraders. They also touch on the risk of cardiac toxicities that are associated with these agents, highlighting that longer follow-up is needed to determine the risks associated with BTK degraders. This discussion took place at the 21st International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2024, held in Nice, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
